Therapy News and Research

RSS

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Clostridium difficile (C. difficile) has reached an epidemic state and is the most common infectious cause of diarrhea in hospitals. Health care providers are seeing increased severity and recurrence rates of the infection. In response, Mayo Clinic has opened a C. difficile Clinic at the Rochester campus.

25 Jun 2013

Study finds decrease in risk of death from ischemic stroke in US black children

The excess risk of death from ischemic (due to reduced blood flow), but not hemorrhagic (due to bleeding), stroke in US black children has decreased over the past decade, according to a study by Laura L. Lehman, M.D., of Boston Children's Hospital, and colleagues.

25 Jun 2013

Viewpoints: Mich. gov. says Medicaid expansion would save money, lives; CMS on making medical devices affordable

The people of Michigan elected the members of the state Senate to be leaders, not vacationers. Unfortunately, the Senate forgot that Thursday and adjourned for its summer vacation. It left Lansing without voting on a bill that would provide health care coverage to nearly half a million working Michiganders. Ensuring access to affordable, quality health care is one of the most significant challenges facing Michigan. The Healthy Michigan plan developed over the past several months is a plan that addresses many of the state's needs and reflects the state's values (Gov. Rick Snyder, 6/23).

25 Jun 2013

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.

25 Jun 2013

Rural women with breast cancer less likely to receive radiation therapy after lumpectomy

Rural women with breast cancer are less likely than their urban counterparts to receive recommended radiation therapy after having a lumpectomy, a breast-sparing surgery that removes only tumors and surrounding tissue, a study by Mayo Clinic and others found.

25 Jun 2013

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC).

24 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association 73rd Scientific Sessions in Chicago, IL. The data suggest that PaQ can reduce known barriers to insulin therapy among people with type 2 diabetes, potentially improving their glycemic control.

24 Jun 2013

EHRA White Book reports on current status of arrhythmia treatments in 55 ESC member countries2

The first European data on lead extraction was released today by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). The information is published in the EHRA White Book 20131, launched at EHRA EUROPACE 2013 in Athens, Greece, during 23-26 June.

24 Jun 2013

Researchers discover reason behind failed anti-cancer therapy

Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor cells.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

NeuroSigma's Monarch eTNS System to make Canadian debut at 30th International Epilepsy Congress

NeuroSigma, Inc., a Los Angeles based medical device company, today announced that its Monarch eTNS System for the adjunctive treatment of epilepsy and depression will make its Canadian debut at the 30th International Epilepsy Congress, taking place in Montreal, Canada from June 23 to June 27, 2013.

21 Jun 2013

Therapy News and Research

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Study finds decrease in risk of death from ischemic stroke in US black children

Viewpoints: Mich. gov. says Medicaid expansion would save money, lives; CMS on making medical devices affordable

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rural women with breast cancer less likely to receive radiation therapy after lumpectomy

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

EHRA White Book reports on current status of arrhythmia treatments in 55 ESC member countries2

Researchers discover reason behind failed anti-cancer therapy

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

NeuroSigma's Monarch eTNS System to make Canadian debut at 30th International Epilepsy Congress

Weill Cornell public health study sheds light on hidden cost of terrorism

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Researchers report therapeutic strategy that appears to destroy drug-resistant melanomas

Research findings suggest potent new therapeutic target for certain types of cancer

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News